Copertina

Periostin in Bullous Pemphigoid: A Potential Biomarker of Disease Activity and Severity

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yutong Ran, Xueting Peng, Yumin Xia, Hong Liu, Yale Liu
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Experimental Dermatology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Differential Tumour Necrosis Factor‐Like Weak Inducer of Apoptosis ( TWEAK ) Associations in Pemphigus and Bullous Pemphigoid
di: Shiran Kang, et al.
Pubblicazione: (2026)

Immune Checkpoint Inhibitor‐Related Bullous Pemphigoid: Distinct Clinical and Immunological Profiles
di: Min Zou, et al.
Pubblicazione: (2026)

The Secretome of Bullous Pemphigoid IgG ‐Treated Keratinocytes Induces a Pro‐Inflammatory Eosinophil Response
di: Adrian P. Mansini, et al.
Pubblicazione: (2026)

Dapagliflozin‐Associated Bullous Pemphigoid
di: Xun Feng, et al.
Pubblicazione: (2025)

Immune Checkpoint Inhibitor–Associated Autoimmune Bullous Diseases: Beyond Bullous Pemphigoid
di: Ioannis‐Alexios Koumprentziotis, et al.
Pubblicazione: (2026)

Involvement of Ferroptosis in Bullous Pemphigoid Pathogenesis
di: Shiling Geng, et al.
Pubblicazione: (2025)

Association of Serum Levels of Total‐IgE and Specific antiBP180 IgE Autoantibodies With Disease Activity and Severity in Patients With Bullous Pemphigoid
di: Aikaterini Kyriakou, et al.
Pubblicazione: (2025)

Extension of Secukinumab and Ixekizumab Dose for Moderate‐To‐Severe Psoriasis in Low Disease Activity Intervals
di: Caiyu Wang, et al.
Pubblicazione: (2025)

Reassessing Ferroptosis in Bullous Pemphigoid: Methodological and Translational Considerations
di: Yang Li
Pubblicazione: (2025)

Management of Bullous Pemphigoid in Special Populations: A Narrative Review of the Literature
di: Giulia Gasparini, et al.
Pubblicazione: (2025)

Lymphocyte Transformation Tests and Patch Tests to Identify Drugs Potentially Associated With Bullous Pemphigoid Development
di: Belen de Nicolas‐Ruanes, et al.
Pubblicazione: (2025)

Use of Lebrikizumab in Treatment‐Refractory Bullous Pemphigoid: Two Reports
di: Christoph Zeyen, et al.
Pubblicazione: (2026)

A Case of Bullous Pemphigoid in a Patient With Systemic Sarcoidosis and Relapsing Polychondritis
di: Takehiro Nakamura, et al.
Pubblicazione: (2025)

Pediatric Bullous Pemphigoid Treated With Dupilumab: A Case Report With Good Response
di: Aldana Belén Almassio, et al.
Pubblicazione: (2025)

Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study
di: Gianluca Avallone, et al.
Pubblicazione: (2025)

A Case of Bullous Pemphigoid Coexisted With Psoriasis Vulgaris Successfully Treated by Apremilast
di: Haruna Kumagai, et al.
Pubblicazione: (2026)

Serum Nectin‐4 as a Potential Prognostic Biomarker for Extramammary Paget Disease
di: Hiromichi Morita, et al.
Pubblicazione: (2025)

BP230 ‐Type Bullous Pemphigoid is a Rare Subset of Bullous Pemphigoid Associated With a Favorable Prognosis: A Retrospective Analysis From a Tertiary Referral Center
di: Roberto Maglie, et al.
Pubblicazione: (2025)

Tissue Eosinophil Counts: A Promising Marker for Optimizing Omalizumab Treatment in Bullous Pemphigoid
di: Gülfem Akin, et al.
Pubblicazione: (2025)

Real‐World Evidence of Dupilumab's Efficacy in Reducing Autoantibodies to Bullous Pemphigoid Antigens
di: Kateryna Karpoff, et al.
Pubblicazione: (2026)

Identification of Polyamine Metabolism‐Related Biomarkers in Psoriasis: A Study Based on Transcriptomics and Single‐Cell Sequencing
di: Li Zhang, et al.
Pubblicazione: (2026)

Lichenoid Drug Eruption due to Telmisartan–Hydrochlorothiazide Combination Progressing to Bullous Pemphigoid: A Case Report
di: Satoko Minakawa, et al.
Pubblicazione: (2025)

Epidermolysis Bullosa Acquisita due to Epitope Spreading in a Patient With Recurrent Bullous Pemphigoid
di: Athina‐Ioanna Daponte, et al.
Pubblicazione: (2025)

Revisiting the Pathology of Bullous Pemphigoid: Basal Cell Necrosis as a Diagnostic Clue and Its Pathogenic Role
di: Hsuan Chen, et al.
Pubblicazione: (2025)

Tissue Levels of MMP‐9 and Granzyme B in Patients With Bullous Pemphigoid: A Case–Control Study
di: Hoa Dinh Pham, et al.
Pubblicazione: (2026)

Effect of IL‐23p19 Inhibitors for Psoriasis With Bullous Pemphigoid: Clinical Insights From Two Cases
di: Sora Sugai, et al.
Pubblicazione: (2025)

JAK Inhibitors for Pemphigoid Diseases
di: Enkhbilguun Sodbuyan, et al.
Pubblicazione: (2025)

Lichen Planus Pemphigoides as an Adverse Reaction to Medication Use: A Retrospective Analysis of Commonly Implicated Medication Triggers Using the FDA Adverse Events Reporting Database
di: Gaurav N. Pathak, et al.
Pubblicazione: (2025)

DUSP6 Regulates Skin Inflammation, Parakeratosis and Disease Severity in a Murine Model of Psoriasis
di: Teresina Laragione, et al.
Pubblicazione: (2026)

Dual Immune‐Related Toxicities: Secukinumab‐Induced Bullous Pemphigoid Following ICI ‐Associated Psoriasis in a Cancer Patient
di: Ioanna A. Paschou, et al.
Pubblicazione: (2025)

Biologic Efficacy by BMI in Moderate‐To‐Severe Psoriasis: A Real‐World Cohort Study
di: Xin Shen, et al.
Pubblicazione: (2026)

Development of Japanese versions of the Autoimmune Bullous Disease Quality of Life and Treatment of Autoimmune Bullous Disease Quality of Life questionnaires
di: Chika Tanemura, et al.
Pubblicazione: (2025)

Identification of Potential Hub Genes in Alopecia Areata
di: Runqiu Liu, et al.
Pubblicazione: (2024)

Semaphorin 7a Regulates the Expression of IL‐4 and IL‐33 in a Cell Model of Atopic Dermatitis and Is Associated With Disease Severity
di: Mindy Ming‐Huey Guo, et al.
Pubblicazione: (2025)

Severe Darier's Disease by Mitochondrial DNA Insertion Causing Nonsense Mutations: In Silico Prediction of a Pathophysiological Mechanism to a Novel Mutation
di: Haruna Shintani, et al.
Pubblicazione: (2025)

Clinical Validation of Imaging Biomarkers in Mycosis Fungoides
di: Selinde S. Wind, et al.
Pubblicazione: (2026)

Long‐Term Effectiveness of Dupilumab in Moderate‐to‐Severe Atopic Dermatitis Across Different Body Regions in Extended Dosing‐Interval Regimens: A Real‐World Chinese Study
di: Yunmin Zou, et al.
Pubblicazione: (2025)

eIF4E: A New Diagnostic Biomarker for Mycosis Fungoides
di: Nicole Golob‐Schwarzl, et al.
Pubblicazione: (2026)

The Role of Bile Acid in Immune‐Mediated Skin Diseases
di: Huike Ma, et al.
Pubblicazione: (2025)

A Case of DPP ‐4 Inhibitor‐Associated Bullous Pemphigoid With Anti‐ LAD ‐1 IgG Antibodies Arising From a Post‐Traumatic Scar
di: Momoko Sasamoto, et al.
Pubblicazione: (2025)